Bioporto AS (LTS:0JJM) Stock Price, Trades & News

Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	7.3
Equity-to-Asset	0.68
Debt-to-Equity	0.12
Debt-to-EBITDA	-0.09
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	3.36	Distress Grey Safe
Beneish M-Score	-2.9	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-6.2
	3-Year EBITDA Growth Rate	13.2
	3-Year EPS without NRI Growth Rate	13.5
	3-Year FCF Growth Rate	4.8
	3-Year Book Growth Rate	-14.3
	Future 3-5Y Total Revenue Growth Rate Estimate	52.25

Momentum Rank

9/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	4.88
	9-Day RSI	11.69
	14-Day RSI	16.4

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.25
	Quick Ratio	2.9
	Cash Ratio	2.1
	Days Inventory	222.78
	Days Sales Outstanding	74.96
	Days Payable	305.38

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-12.5
	Shareholder Yield %	-13.29

Profitability Rank

1/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	75.44
	Operating Margin %	-213.7
	Net Margin %	-203.83
	EBITDA Margin %	-209.9
	FCF Margin %	-194.69
	OCF Margin %	-191.29
	ROE %	-155.17
	ROA %	-97.77
	ROIC %	-253.4
	3-Year ROIIC %	212.35
	ROC (Joel Greenblatt) %	-820.42
	ROCE %	-148.02

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	13.58
	PB Ratio	9.41
	Price-to-Tangible-Book	9.33
	EV-to-EBIT	-6.34
	EV-to-EBITDA	-6.52
	EV-to-Forward-EBITDA	11.66
	EV-to-Revenue	13.69
	EV-to-Forward-Revenue	21.05
	EV-to-FCF	-6.94
	Price-to-GF-Value	0.76
	Price-to-Median-PS-Value	0.73
	Price-to-Net-Current-Asset-Value	11.2
	Price-to-Net-Cash	22.4
	Earnings Yield (Greenblatt) %	-15.78
	FCF Yield %	-13.1

GF Value™: kr1.47

LTS:0JJM

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with 0JJM. Try a 7-Day Free Trial to check it out.

Bioporto AS Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Bioporto AS Stock Events

Financials Calendars

Event	Date	Price (kr)
Third quarter earnings results for 2026	2026-11-19 09:00	In 92 days
Third quarter earnings conference call for 2026	2026-11-19	In 91 days
Second quarter earnings conference call for 2026	2026-08-20 14:00	In 1 day
Second quarter earnings results for 2026	2026-08-20	1.12 (+0.00%)
First quarter earnings conference call for 2026	2026-05-21 11:00	1.22 (+0.00%)
First quarter earnings results for 2026	2026-05-21	1.22 (+0.00%)
General meeting for 2025	2026-04-24 15:00	1.22 (+0.00%)
Annual report for 2025	2026-03-26	1.22 (+0.00%)
Third quarter earnings conference call for 2025	2025-11-19 11:00	1.22 (+0.00%)
Third quarter earnings results for 2025	2025-11-19	1.22 (+0.00%)

Show

Entries

Press Release

	Subject	Date
	Life Science Outsourcing, Inc. Welcomes Neil A. Goldman as Chief Financial Officer	2023-10-17

10/Page

Articles on Bioporto AS

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.